当前位置: X-MOL 学术Coord. Chem. Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
State of the art in organometallic ruthenium metallodrugs for breast cancer treatment: Advances and innovations
Coordination Chemistry Reviews ( IF 20.3 ) Pub Date : 2024-10-22 , DOI: 10.1016/j.ccr.2024.216252
Elena Domínguez-Jurado, Agustín Lara-Sánchez, Iván Bravo, Alberto Ocaña, Carlos Alonso-Moreno

Cancer is a major health concern and a leading cause of death worldwide. Among all cancer types, breast cancer has the highest incidence rate. The treatment of breast cancer encompasses the use of different drugs, with ruthenium metallodrugs emerging as promising alternatives to platinum derivatives. In this context, organometallic ruthenium(II) compounds are currently the most widely explored.

中文翻译:


用于乳腺癌治疗的有机金属钌金属药物的最新进展:进步和创新



癌症是全球主要的健康问题和主要死亡原因。在所有癌症类型中,乳腺癌的发病率最高。乳腺癌的治疗包括使用不同的药物,其中钌金属药物成为铂衍生物的有前途的替代品。在此背景下,有机金属钌 (II) 化合物是目前探索最广泛的化合物。
更新日期:2024-10-22
down
wechat
bug